Holdings Channel



Play Video: The Importance of Insider Buying


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree ICVX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Other companies seeing insider buying close in time to when the ICVX Insider Buying occurred are:

KZR Insider Buying
RIBT Insider Buying
VGI Insider Buying
BNFT Insider Buying
ICAD Insider Buying
GEVO Insider Buying
MQT Insider Buying
VINO Insider Buying
SEEL Insider Buying
SPLP Insider Buying

ICVX insider buying image
The table below summarizes the most recent ICVX insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why ICVX insider buys are important for investors to follow.
DateInsiderPriceAmount
3-29-2022
Insider Buy
RA CAPITAL MANAGEMENT, L.P.
Director and >10% Owner
$4.54
CAGR »
$836,882.74
184,218 shares
8-2-2021
Insider Buy
NanoDimension III, L.P.
$15.00
CAGR »
$2,000,010.00
133,334 shares
8-2-2021
Insider Buy
RA CAPITAL MANAGEMENT, L.P.
Director and >10% Owner
$15.00
CAGR »
$39,999,990.00
2,666,666 shares
8-2-2021
Insider Buy
ADAMS STREET PARTNERS LLC
$15.00
CAGR »
$2,000,010.00
133,334 shares
8-2-2021
Insider Buy
Terry P. Gould
Director
$15.00
CAGR »
$2,000,010.00
133,334 shares
8-2-2021
Insider Buy
Niranjan Kanesa-thasan
Chief Medical Officer
$15.00
CAGR »
$99,990.00
6,666 shares
8-2-2021
Insider Buy
Qiming U.S. Healthcare Fund II, L.P.
$15.00
CAGR »
$3,320,265.00
221,351 shares
8-2-2021
Insider Buy
Sanofi
>10% Owner
$15.00
CAGR »
$1,000,005.00
66,667 shares

Also See: Institutional Holders of ICVX
Also See: SEC filings

ICVX Performance Since Insider Purchase
Below we present the annualized performance delivered by ICVX stock since 3-29-2022 (the date of the most recent insider purchase). The performance of the investment from the time ICVX insider buying occurred is the ultimate test of whether insiders were right about ICVX being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 03/30/2022
End date: 02/20/2024
Start price/share: $5.33
End price/share: $15.31
Dividends collected/share: $0.00
Total return: 187.24%
Average Annual Total Return: 74.46%
Starting investment: $10,000.00
Ending investment: $28,722.94
Years: 1.90

ICVX Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent ICVX insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding ICVX

ICVX Insider Buying | www.HoldingsChannel.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.